Efficacy of ICT with DFX , MDS,AA
 

1125 A Multi-Center, Open Label Study Evaluating the Efficacy of Iron Chelation Therapy with Deferasirox In Transfusional Iron Overload Patients with Myelodysplastic Syndromes or Aplastic Anemia Using Quantitative R2 mri

http://ash.confex.com/ash/2010/webpr...aper33861.html

The South Korean study wanted to investigate the benefits of Deferasirox/Exjade for reduction of LIC in transfusion-related iron overload patients with MDS or AA, as there had not been many studies on this before.

There were 97 persons enrolled in this study. ""Deferasirox was given orally at a dose of 20 mg/kg/day for at least 6 months to all patients."

Citation: "This study clearly shows that deferasirox is effective in reducing LIC and serum ferritin level in transfusional iron overload patients with MDS or AA, even with ongoing transfusion requirement, and well tolerated."

An extension study will look at "the beneficial effects of deferasirox on prolonging survival and improving quality of life in these patients."